Menstrual cycle alterations in reproductive age women after anti COVID-19 vaccination. A survey in 419 Italian women and quality of life and sexual function evaluation.


Journal

Minerva obstetrics and gynecology
ISSN: 2724-6450
Titre abrégé: Minerva Obstet Gynecol
Pays: Italy
ID NLM: 101777346

Informations de publication

Date de publication:
15 Sep 2023
Historique:
medline: 15 9 2023
pubmed: 15 9 2023
entrez: 15 9 2023
Statut: aheadofprint

Résumé

Pharmacovigilance agencies did not collect data regarding menstrual changes after COVID-19 vaccination even if many women experienced it. Our aim was to evaluate whether COVID-19 vaccination is associated with secondary changes in menstrual cycle and to assess both quality of life (QoL) and sexual function (SF). This study is a retrospective analysis referred to our Department from January 2021 to December 2021. The study cohort responded to same questionnaires before the second dose of vaccination (referring to previous 3 months) and 3 months after that (referring to three menstrual cycles after full-dose vaccination). The surveys administered were FSFI, FSDS, SF-36, MEDI-Q and the VAS-scale for dysmenorrhea. Four-hundred-nineteen vaccinated women were included in the study. The survey did not show a significant change in menstrual cycle length before and after COVID-19 vaccine (5.88±3.67 vs. 4.97±2.89, P=0.21); the interval between periods was significantly higher after a full-cycle vaccination (28.32±7.34 vs. 32.38±7.45, P<0.02); 32 patients (7.6%) developed amenorrhea after the second dose; VAS Scale did not change significantly (median range 3 (3-5) vs. 4 (3-6), P=0.20). MEDI-Q did not show significant variations before and after the vaccination (43.21±11.65 vs. 40.28±9.88, P=0.35). QoL and SF did not change significantly (FSFI median 27 [24-29] vs. 28 [25-30], P=0.12, FSDS median 9 [5-11] vs. 8 [4-12], P=0.22), SF-36 median 81 [70-85] vs. 82 [72-86], P=0.43). COVID-19 vaccination is associated with a significant change in intervals between menstrual cycles without other alterations in menstrual characteristics, in QoL or SF.

Sections du résumé

BACKGROUND BACKGROUND
Pharmacovigilance agencies did not collect data regarding menstrual changes after COVID-19 vaccination even if many women experienced it. Our aim was to evaluate whether COVID-19 vaccination is associated with secondary changes in menstrual cycle and to assess both quality of life (QoL) and sexual function (SF).
METHODS METHODS
This study is a retrospective analysis referred to our Department from January 2021 to December 2021. The study cohort responded to same questionnaires before the second dose of vaccination (referring to previous 3 months) and 3 months after that (referring to three menstrual cycles after full-dose vaccination). The surveys administered were FSFI, FSDS, SF-36, MEDI-Q and the VAS-scale for dysmenorrhea.
RESULTS RESULTS
Four-hundred-nineteen vaccinated women were included in the study. The survey did not show a significant change in menstrual cycle length before and after COVID-19 vaccine (5.88±3.67 vs. 4.97±2.89, P=0.21); the interval between periods was significantly higher after a full-cycle vaccination (28.32±7.34 vs. 32.38±7.45, P<0.02); 32 patients (7.6%) developed amenorrhea after the second dose; VAS Scale did not change significantly (median range 3 (3-5) vs. 4 (3-6), P=0.20). MEDI-Q did not show significant variations before and after the vaccination (43.21±11.65 vs. 40.28±9.88, P=0.35). QoL and SF did not change significantly (FSFI median 27 [24-29] vs. 28 [25-30], P=0.12, FSDS median 9 [5-11] vs. 8 [4-12], P=0.22), SF-36 median 81 [70-85] vs. 82 [72-86], P=0.43).
CONCLUSIONS CONCLUSIONS
COVID-19 vaccination is associated with a significant change in intervals between menstrual cycles without other alterations in menstrual characteristics, in QoL or SF.

Identifiants

pubmed: 37712930
pii: S2724-606X.23.05347-2
doi: 10.23736/S2724-606X.23.05347-2
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Melania Loggia (M)

Department of Gynecology and Obstetrics, Sandro Pertini Hospital, Rome, Italy - melaloggia1@gmail.com.
Department of Surgical Sciences, Section of Gynecology and Obstetrics, Tor Vergata University, Rome, Italy - melaloggia1@gmail.com.

Anna DI Pinto (A)

Department of Gynecology and Obstetrics, Anzio Hospital, Anzio, Rome, Italy.

Claudia Morgani (C)

Department of Gynecology and Obstetrics, Sandro Pertini Hospital, Rome, Italy.
Department of Surgical Sciences, Section of Gynecology and Obstetrics, Tor Vergata University, Rome, Italy.

Giorgia Cardella (G)

Department of Gynecology and Obstetrics, Sandro Pertini Hospital, Rome, Italy.
Department of Surgical Sciences, Section of Gynecology and Obstetrics, Tor Vergata University, Rome, Italy.

Alessia Contadini (A)

Department of Gynecology and Obstetrics, Sandro Pertini Hospital, Rome, Italy.
Department of Surgical Sciences, Section of Gynecology and Obstetrics, Tor Vergata University, Rome, Italy.

Pier L Palazzetti (PL)

Department of Gynecology and Obstetrics, Sandro Pertini Hospital, Rome, Italy.

Francesca Macrì (F)

Department of Gynecology and Obstetrics, Sandro Pertini Hospital, Rome, Italy.

Paolo R Moro (PR)

Department of Gynecology and Obstetrics, Anzio Hospital, Anzio, Rome, Italy.

Vincenzo Spina (V)

Protection of Maternal and Child Health Unit, Rieti, Italy.

Andrea Morciano (A)

Department of Obstetrics and Gynecology, Cardinal Panico Hospital, Tricase, Lecce, Italy.

Herbert C Valensise (HC)

Department of Surgical Sciences, Section of Gynecology and Obstetrics, Tor Vergata University, Rome, Italy.

Michele C Schiavi (MC)

Department of Gynecology and Obstetrics, Sandro Pertini Hospital, Rome, Italy.

Classifications MeSH